Bristol CABG Drug Fails Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb is terminating its collaboration with Corgentech on the development of the coronary artery bypass graft agent edifoligide (E2F Decoy)